Proton Therapy: Changing Cancer Treatment
Approximately 50% of cancers require some form of radiation therapy. A proton therapy unit can significantly impact the treatment of up to 10% of that number, for a total of up to 400 patients a year. In our never-ending quest to help eradicate cancer, HHS Healthcare has added this advanced treatment to our offerings.
As part of our total packaged solution from concept to treating your first patient, we can provide a proton therapy system as a standalone solution, as part of a solution that includes additional forms of radiation treatment, or as a seamless addition to your existing healthcare facility or practice. The approximately 14,000 square foot proton suite includes a reception area, changing rooms, and additional areas that house the equipment.
Our comprehensive and proven services take the worry and guesswork out of a cutting-edge project of this magnitude. This can include helping you through the extensive regulation process that varies by state and country.
Proton Therapy Over Traditional Treatments:
Minimizes Radiation Exposure
Protons can be manipulated to release energy precisely where it is needed. This targeted approach at any depth or location results in minimal radiation passing through healthy tissue in front of the cancer. Upon exit, the radiation dose is nearly zero, minimalizing radiation to those healthy cells.
Greatest Possibility of Retreatment
Other radiation methods can be forced to limit the amount of treatment a patient can receive. Due to the specificity of the proton delivery and the lower damage to surrounding healthy tissue, additional treatment sessions can be administered in the advent of new or recurring tumors.
Improve the Quality of Life for Patients
The treatment session itself is painless. Less radiation affecting the surrounding healthy tissue can mean fewer side effects immediately following treatment, including nausea, vomiting, and diarrhea.
Reduces the Risk of Secondary Cancers
By utilizing precisely targeted protons, there is a lower chance of metastasis, less likelihood of recurrence, and the limited dose exposure to collateral tissue decreases the risk for other cancers.